uniQure (NASDAQ:QURE) Shares Gap Up - Should You Buy?

Key Points

• uniQure shares opened higher, rising from a previous close of $20.97 to $21.94 before trading at approximately $21.87.
• Analyst sentiment was mostly positive, with a consensus “Moderate Buy” rating and an average price target of $53.25; targets ranged as high as $70.
• The biotechnology company remains unprofitable, reporting a quarterly loss of $1.22 per share versus an expected loss of $0.82, while institutional investors owned 78.83% of its stock.

uniQure N.V. (NASDAQ:QURE - Get Free Report)'s share price gapped up prior to trading on Thursday. The stock had previously closed at $20.97, but opened at $21.94. uniQure shares last traded at $21.8710, with a volume of 256,843 shares trading hands.

Analysts Set New Price Targets

A number of research analysts recently issued reports on QURE shares. HC Wainwright reaffirmed a "buy" rating on shares of uniQure in a report on Tuesday, September 29th. Cantor Fitzgerald upgraded shares of uniQure from a "neutral" rating to an "overweight" rating and set a $61.00 price target on the stock in a research report on Wednesday, June 17th. Leerink Partners upped their price target on shares of uniQure from $36.00 to $70.00 and gave the company an "outperform" rating in a report on Thursday, June 18th. Wall Street Zen lowered shares of uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, September 5th. Finally, William Blair upgraded shares of uniQure to a "strong-buy" rating in a research report on Wednesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $53.25.

uniQure Price Performance

The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -5.43 and a beta of 1.06. The stock has a 50-day moving average of $40.21 and a two-hundred day moving average of $33.83.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%. The company had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.45 million. During the same quarter in the previous year, the firm posted ($0.69) EPS. On average, analysts anticipate that uniQure N.V. will post -3.82 EPS for the current year.

Institutional Trading of uniQure

Institutional investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP acquired a new stake in uniQure during the second quarter valued at $15,254. IFP Advisors Inc grew its stake in shares of uniQure by 39.8% in the 2nd quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company's stock valued at $128,000 after buying an additional 791 shares in the last quarter. Stephens Inc. AR acquired a new position in uniQure in the first quarter worth approximately $182,000. Cannon Global Investment Management LLC acquired a new position in uniQure in the first quarter worth approximately $199,000. Finally, Rangeley Capital LLC raised its position in uniQure by 52.9% during the first quarter. Rangeley Capital LLC now owns 13,000 shares of the biotechnology company's stock valued at $213,000 after acquiring an additional 4,500 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients' cells, with the goal of addressing the underlying causes of disease through a single administration.

uniQure's lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.